SGSN:SIXSGS SA Analysis
Data as of 2026-03-11 - not real-time
CHF 92.38
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
SGS SA (SGSN.SW) is trading at CHF 92.38, just above the near‑term support of CHF 90.20 and below both the 20‑day and 50‑day SMAs (≈CHF 94), indicating a modest cushion but still under pressure from a bearish MACD histogram. Volume is increasing and the 30‑day volatility is high at ~23.5%, suggesting active price swings while the low beta (~0.30) tempers market‑wide risk. The stock’s PE of 26.7 is slightly below the industry average of 29.4, yet the price‑to‑book ratio of 19.8 is extremely elevated, and the DCF fair value of CHF 49.6 is far below the current price, hinting at limited upside beyond the modest 6.6% upside estimate.
Fundamentally, SGS delivers a solid dividend yield of 3.49% with a high payout ratio (~92%), but its balance sheet is heavily leveraged (debt‑to‑equity > 490) and cash reserves cover less than half of total debt. Operating margins are healthy (≈15%) and ROE is exceptionally high, but the combination of high leverage and near‑full dividend payout raises questions about long‑term dividend sustainability. The company benefits from a diversified global footprint and a stable regulatory environment for testing and certification services, supporting a “blend” growth‑value profile despite the current valuation pressures.
Fundamentally, SGS delivers a solid dividend yield of 3.49% with a high payout ratio (~92%), but its balance sheet is heavily leveraged (debt‑to‑equity > 490) and cash reserves cover less than half of total debt. Operating margins are healthy (≈15%) and ROE is exceptionally high, but the combination of high leverage and near‑full dividend payout raises questions about long‑term dividend sustainability. The company benefits from a diversified global footprint and a stable regulatory environment for testing and certification services, supporting a “blend” growth‑value profile despite the current valuation pressures.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price hovering just above key support level
- Bearish MACD divergence despite bullish trend label
- Increasing trading volume indicating short‑term interest
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Potential upside toward resistance around CHF 97.5
- Attractive dividend yield relative to peers
- Forward PE improvement to ~20x supporting valuation
Long Term
> 3 yearsNeutral
Model confidence: 6/10
Key Factors
- High leverage and near‑full dividend payout risk
- Strong brand and global diversification in a regulated industry
- Elevated price‑to‑book ratio limiting long‑term upside
Key Metrics & Analysis
Financial Health
Revenue Growth1.90%
Profit Margin9.62%
P/E Ratio26.7
ROE76.60%
ROA8.41%
Debt/Equity492.16
P/B Ratio19.8
Op. Cash FlowCHF1.2B
Free Cash FlowCHF805.5M
Industry P/E29.4
Technical Analysis
TrendBullish
RSI43.7
SupportCHF 90.20
ResistanceCHF 97.48
MA 20CHF 94.03
MA 50CHF 94.03
MA 200CHF 87.61
MACDBearish
VolumeIncreasing
Fear & Greed Index76.91
Valuation
Fair ValueCHF 49.64
Target PriceCHF 98.47
Upside/Downside6.59%
GradeFair
TypeBlend
Dividend Yield3.49%
Risk Assessment
Beta0.30
Volatility23.49%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.